News
- 29Jun
2026Alebund Pharmaceuticals (09637.HK) Debuts on the HKEx Main Board - 09Jun
2026Windward Bio Doses First Patients in Phase 2 SIRIUS COPD Study of Ultra Long- Acting Anti-TSLP Antibody WIN378 - 08Jun
2026OriCell’s GPC3 CAR-T Receives NMPA Clearance for Confirmatory Phase II Trial in Late-Line Advanced Hepatocellular Carcinoma - 08Jun
2026China NMPA Grants IND Clearance to Adcentrx Therapeutics’ ADRX-0405 STEAP1 ADC for the Treatment of Late-Stage Solid Tumors, Including Prostate Cancer - 04Jun
2026Tempest Therapeutics Appoints Drake Richey and John Yee, MD, MPH to Board of Directors - 01Jun
2026Rallybio Corporation and Avenzo Therapeutics Announce Merger Agreement to Advance Next-Generation Oncology Therapies and $215 Million Concurrent Private Placement - 29May
2026Tempest Therapeutics Announces Warrant Exercise for Approximately $2 Million in Gross Proceeds - 28May
2026Avenzo Therapeutics Announces First Patient Dosed in Combination Cohort Evaluating CDK4 Selective Inhibitor (AVZO-023) with CDK2 Selective Inhibitor (AVZO-021) In Ongoing Phase 1/2 ORION-1 Study - 28May
2026Zenas BioPharma Anounces Submision of Biologics License Aplication (BLA) to U.S. FDA for Obexelimab in IgG4-RD FDA for Obexelimab in IgG4-RD - 18May
2026Design Therapeutics Announces Four-Week IV Data from the RESTORE-FA Trial of DT-216P2 Demonstrating Clinical Improvements and Comprehensive Biomarker Activity in Friedreich Ataxia - 06May
2026Alebund Pharmaceuticals Announces Completion of Patient Enrollment in Global Phase III Pivotal Multi-Regional Clinical Trial of AP301 for Hyperphosphatemia - 05May
2026Sail Biomedicines Appoints Gene Marcantonio, M.D., Ph.D., as Chief Medical Officer - 04May
2026Windward Bio Announces $165M Crossover Financing to Advance Pipeline of Long- Acting Immunology Therapies With Best-in-Disease Potential - 04May
2026NextCure and Simcere Zaiming Initiate Dose Optimization for SIM0505 (CDH6 ADC) in Gynecologic Cancers - 28Apr
2026Avenzo Therapeutics Advances the Combination of CDK4 Selective Inhibitor (AVZO-023) with CDK2 Selective Inhibitor (AVZO-021) in Ongoing Phase 1/2 ORION-1 Study in HR+/HER2- Breast Cancer - 22Apr
2026Tempest Announces Key Manufacturing Milestone for TPST-2003 Dual-Targeting CD19/BCMA CAR-T - 14Apr
2026Tempest Appoints Andrew Fang, Ph.D., as Head of Business Development to Advance Strategic Partnerships and Global Licensing Efforts - 10Apr
2026Oricell Therapeutics Closes $110 Million Pre-IPO Financing to Accelerate Global Development of Solid Tumor CAR-T Therapies - 07Apr
2026NextCure Receives Fast Track Designation for SIM0505 (CDH6 ADC) in Ovarian Cancer - 27Mar
2026Zenas BioPharma Anounces Pricing of Concurent Public Oferings of 2.50% Convertible Senior Notes Due 2032 and Comon Stock with Agregate Gros Proceds of $30.0 Milion Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $300.0 Million - 23Mar
2026Tempest Therapeutics Announces Up To $6 Million Private Placement - 18Mar
2026Alebund Pharmaceuticals Announces Collaboration and License Agreement with R1 Therapeutics for AP306 - 11Mar
2026Tempest Announces Partnership for TPST-2003 in Preparation for Planned U.S. Registrational Study in 2026 - 23Feb
2026Gilead Sciences to Acquire Arcellx to Maximize Long-term Potential of Anito-cel - 11Feb
2026Tempest Lays Out Strategic Plan to Advance Recently Acquired Dual-Targeting CAR-T Assets - 09Feb
2026Zenas BioPharma Anounces Late-Breaking Platform Presentation of Results from Phase 2 MonStone Trial of Obexelimab in Relapsing Multiple Sclerosis at ACTRIMS Forum 2026 MoonStone Trial of Obexelimab in Relapsing Multiple Sclerosis at ACTRIMS Forum 2026 - 12Jan
2026Oricell Therapeutics Announces $70M Initial Closing of Series C Financing, to Accelerate Global Development of Solid Tumor CAR-T Therapies - 05Jan
2026Zenas BioPharma Anounces Positive Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Imunoglobulin G4-Related Disease (IgG4-RD) Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD) - 26Dec
2025Adicet Bio Announces Reverse Stock Split - 21Dec
2025Windward Bio Expands Immunology Pipeline With WIN027, a Long-Acting, Clinical-Stage Bispecific Targeting TSLP and IL-13 - 15Dec
2025Zenas BioPharma's Partner, InoCare Pharma, Anounces Achievement of Primary Endpoint in Phase 2b Study of Orelabrutinib, a BTK Inhibitor, for Systemic Lupus Erythematosus in Phase 2b Study of Orelabrutinib, a BTK Inhibitor, for Systemic Lupus Erythematosus - 26Nov
2025Tempest Announces Closing of Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules - 24Nov
2025Avenzo Therapeutics Granted Fast Track Designation for AVZO-103, a Potential Best-in-Class Nectin4/TROP2 Bispecific Antibody-Drug Conjugate, for the Treatment of Patients with Urothelial Cancer Previously Treated with Enfortumab Vedotin - 19Nov
2025Avenzo Therapeutics Announces Appointment of Scott Lipman as Chief Financial Officer - 17Nov
2025NextCure Announces Closing of $21.5 Million PIPE Financing in Advance of First Half 2026 Phase 1 POC Data Readouts - 23Oct
2025Sail Biomedicines Appoints Martin Mackay, Ph.D., to Its Board of Directors - 16Oct
2025NextCure and Simcere Zaiming Announce Expansion of Ongoing Phase 1 Trial of SIM0505 (CDH6 ADC) into the United States - 16Oct
2025Adicet Bio Announces First Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Treatment- Refractory Rheumatoid Arthritis (RA) - 08Oct
2025Zenas BioPharmand InoCare Pharma Anounce License Agrement Granting Zenas Rights for Thre Autoimune Product Candidates, Including Orelabrutinib, a BTK Inhibitor in Phase 3 Development for Multiple Sclerosis Rights for Three Autoimmune Product Candidates, Including Orelabrutinib, a BTK Inhibitor in Phase 3 Development for Multiple Sclerosis - 07Oct
2025Adicet Bio, Inc. Announces $80 Million Registered Direct Offering
…